Form 8-K NEUROCRINE BIOSCIENCES For: Feb 11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Oil rises on Iran war stalemate; near-term potential for further gains seen limited
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Neurocrine Bio. (NBIX) PT Lowered to $150 at Oppenheimer
February 14, 2022 8:30 AM ESTOppenheimer analyst Jay Olson lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $150.00 (from $154.00) while maintaining an Outperform rating.
The analyst commented, "NBIX shares have outperformed in 2022 (+7% vs. NBI -14% and S&P 500 -7% YTD) based on a favorable setup that... More
Neurocrine Biosciences (NBIX) Misses Q4 EPS by 54c
February 11, 2022 7:32 AM ESTNeurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $0.04, $0.54 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $303.5 million versus the consensus estimate of $320 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
... More